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Signal enhancement by hyperpolarization is a way of overcoming the low sensitivity in magnetic 
resonance; MRI in particular. One of the most well-known methods, dissolution Dynamic Nuclear 
Polarization, has been used clinically in cancer patients. One way of ensuring a low bioburden of 
the hyperpolarized product is by use of a closed fluid path that constitutes a barrier to 
contamination. The fluid path can be filled with the pharmaceuticals, i.e. imaging agent and 
solvents, in a clean room, and then stored or immediately used at the polarizer. In this study, we 
present a method of filling the fluid path that allows it to be reused. The filling method has been 
investigated in terms of reproducibility at two extrema, high dose for patient use and low dose for 
rodent studies, using [1-13C]pyruvate as example. We demonstrate that the filling method allows 
high reproducibility of six quality control parameters with standard deviations 3-10 times smaller 






Quality control (process capability)  
Pyruvate conc. (mM) 246±19 
pH 7.71±0.17 
EPA conc. (µM) 1.17±0.28 
Temperature (⁰C) 32.0±1.5 
Volume (mL) 44.2±1.0 
Polarization (%) 34.2±2.9 
QC output 
HIGHLIGHTS 
• d-DNP of sample sizes up to 1 mL  
• d-DNP with re-useable plastic fluid path 
• Reproducibility data for [1-13C]pyruvate for the clinical formulation  
INTRODUCTION 
Increase of the NMR signal of molecules by hyperpolarization is a technique, which has many 
applications in the field of NMR spectroscopy and imaging. The most commonly used method is 
dissolution-Dynamic Nuclear Polarization (d-DNP) [1], in which the hyperpolarized nuclear spins 
are transferred from the solid state to the liquid state by a quick dissolution while retaining the 
nuclear spin polarization.  
In this study, the d-DNP technique will be demonstrated by hyperpolarization of pyruvate; being a 
key intersection in various metabolic pathways, [1-13C]pyruvate is by far the most common 
molecule for studies with d-DNP [2] [3]. It has an advantageously long relaxation time T1 and high 
polarization levels can be achieved [4]. Other molecules can be used to probe biological pathways 
as well; [U-13C;U-2H]glucose [5], [1,4-13C2]fumarate [6], [1-13C]bicarbonate [7] among many other 
biologically relevant molecules. Similarly, hyperpolarized 13C-labelled biologically inert molecules 
have been applied for angiography and perfusion studies [8] [9]. Besides the bioprobe, an electron 
paramagnetic agent (EPA) should be present to enable Dynamic Nuclear Polarization. The 
commonly used EPAs for hyperpolarization are OXO63 [10], BDPA [11] and TEMPO [12]. In this 
study, AH111501 is used, a stable trityl radical, which precipitates in low pH and can be removed 
by filtration in the receiver previous to the neutralization step. In 2013, the first clinical study with 
hyperpolarized [1-13C]pyruvate was published, demonstrating technical feasibility and showing 
promising results in the phase I trial on patients with prostate cancer [13].  
Studies on the performance of the d-DNP process with the aim of demonstrating efficient 
dissolution, i.e. high concentration and large volume with minimal loss of polarization have been 
published [14] [15]. The principle of dissolution in these studies is the use of a solvent that is heated 
to an elevated temperature to create a vapor pressure that can drive the flow of solvent past the cold, 
polarized sample. In the case of aqueous dissolutions, a temperature of 180 °C is typically used, 
creating a vapor pressure of 10 bar. Another principle of dissolution was introduced in 2011 [16], 
where the concept of a closed fluid path (FP) was presented. The primary objective of the closed FP 
was to secure a sterile environment throughout the polarization and dissolution process [16]. In 
terms of dissolution capability, two key principal differences between the FP and previous designs 
should be noted: 1) the solvent is not driven by the vapor pressure at the given temperature, but by a 
syringe, 2) the independent inlet and outlet tubes are replaced by two concentric tubes with the inlet 
as the inner lumen and with return flow in the outer lumen. From the first point follows that solvent 
temperature can be controlled independently of solvent flow rate. In [17] it was shown that a 
syringe and solvent temperature of 130 °C and piston drive pressure of 16 bar was optimal for the 
dissolution. These conditions are extreme for most plastic materials, but is tolerated by e.g. 
polyphenylsulfones or polyetheretherketones. The second point is expected to affect dissolution 
efficiency, but was introduced to facilitate a dynamic seal that allows sample introduction into the 
cryostat through an air lock without raising the pressure of the 1 K sample space to atmospheric 
pressure. The FP consists of two major parts: part A, which contains sample and solvent, and allows 
the hyperpolarized solution to leave the polarizer through an open ended tube, and part B, that 
consists of a receiver connecting to the exit tube of part A, allowing non-contact quality control of 
the dissolved product. Part B also includes a filter that removes the EPA in-line with the dissolution 
process. The EPA precipitates in aqueous solution at acidic pH and can be removed effectively by 
mechanical filtration. 
The objective of this work was to study the dissolution capability of the FP for two different sample 
sizes of [1-13C]pyruvic acid. (1) A sample of 1.47 g, producing a human dose, dissolved in 
dissolution medium (DM) and neutralized with Neutralization Medium (NM) to a target 
concentration of 250 mM [1-13C]pyruvate using the SPINlab polarizer and quality control system 
(involving FP part A and B). (2) A sample of 40 mg, producing a small animal dose, dissolved in 
DM to a target concentration of 80 mM, using a home-built polarizer involving only part A of the 
FP. 
 
MATERIALS AND METHODS 
Polarizer 
Large samples were polarized on a SPINlab (GE Healthcare), Fig 1, operating at 5 T and 0.85 K. 
Small samples were polarized on a home built polarizer [1] operating at 6.7 T and 1.1-1.2 K 
modified to accommodate the fluid path dissolution system. 
Sample 
[1-13C]pyruvic acid (PA) (GE Healthcare, Norway) containing 15 mM  AH111501 (EPA), 94.9% 
purity (GE Healthcare, USA). 
Dissolution Medium (DM) 
Large sample: Ultra pure water (CHROMASOLV®Plus HPLC grade, Sigma Aldrich) with 0.1 g/L 
ethylenediaminetetraacetic acid disodium salt dihydrate (EDTA) (VWR). 
Small sample: 0.2 M tris-hydroxymethyl aminomethane (TRIS base) (VWR) with 0.1 g/L EDTA. 
Neutralization Medium (NM) 
Large samples: 0.72 M NaOH (MERCK), 0.4 M TRIS base, 0.1 g/L EDTA. 
Small sample: NaOH (10 M). 
Fluid Path (FP) 
The FP (type 1293, GE Healthcare, USA) used for this study is shown in Fig 1. Part A of the fluid 
path consists of a vial which can hold up to 2 mL of sample, the dynamic seal that allows the tubing 
to move inside the polarizer under vacuum, the co-axial tubing for DM inlet and outlet, the valve 
that opens the inlet and outlet simultaneously and the dissolution syringe that can hold up to 60 mL 
of solvent. Fig 2B and 2C show the vial with the position of the inner tube. The inner tube has a 
nozzle to provide a more efficient dissolution as demonstrated in [15] and [17]. Part B of the FP, 
Fig 1, consists of the transfer tube, the EPA filter, receiver vessel with quality control (QC) 
appendage, the sterile assurance filter and a Medrad 65 mL MR syringe (Bayer, Denmark). On first 
use of the FP, the vial was attached to the outer tube by the use of UV adhesive (Dymax 1161-M). 
On reuse, the FP part A was cleaned with 40 mL washing buffer (10% NM in distilled water), and 
then twice with 40 mL distilled water. Initially, the FP was thoroughly examined for any potential 
defects or irregularities. The FP was placed on a pressure check fixture and briefly flushed with 
Helium gas to secure unhindered flow. Reused FPs containing visible moisture were flushed for 10 
min, or until dry, with compressed air or helium gas. Part B is not reused since it contains a small 
amount of HPTS (8-hydroxypyrene-1,3,6-trisulfonic acid, trisodium salt) dye used for the optical 
pH determination. 
Filling tube for sample addition 
For adding the sample, a syringe with a filling tube (Mikrolab Aarhus A/S, PEEK O.D. 1/32” I.D. 
0.5 mm, 1.5 m, VI JRT5620M3) attached through an adapter, a ferrule and a screw (Tefzel P628, 
Tefzel P200 and Tefzel P215, Mikrolab Aarhus A/S, Denmark) were used. To fit into the adapter, a 
sleeve (Sealtight, 840 um, F247, Mikrolab Aarhus A/S, Denmark) was glued (UV adhesive) onto 
the filling tube, Fig 2. The end of the tube was cut in a slanted manner in order to pass the nozzle 
and minimize residual sample at the end of the tube. Before first use of the filling tube, it was 
inserted through the dissolution syringe valve bore and through the inner tube, all the way to the 
sample vial. When the tube reached the bottom of the empty vial, it was retracted such that the end 
of the tube just passed the nozzle of the inner tube (Fig 2B). Thus no sample would contaminate the 
inner tube upon addition. A mark was put on the filling tube by the dissolution syringe valve bore, 
so the correct position would be easily found upon next use. 
Addition of sample, DM and NM 
a. Addition of large samples 
Approx 0.5 mL of sample was pulled into a 3 mL single use plastic syringe (carefully avoiding air 
bubbles) after which the filling tube was attached. The sample was then pushed through the filling 
tube in order to fill the dead volume (approx. 380 µL). An Eppendorf tube with sample was placed 
on the balance, tared, and sample (1.47 g) was drawn into the syringe. Air (few centimeters) was 
then drawn into the tube to prevent contamination of the FP inner wall. The syringe and filling tube 
were weighted before and after addition, to confirm correct addition of sample. The surface of the 
filling tube was thoroughly cleaned for potential impurities and inserted through the inner tube of 
the FP until the tube reached the bottom of the vial. The slanted tip made it possible for the filling 
tube to pass the nozzle of the inner tube. The filling tube was then retracted to the correct position, 
as indicated by the mark. The sample was carefully added by push of the syringe piston. After 
addition, air was drawn into the filling tube, and it could then be retracted from the FP without 
contaminating the inner tube. 
38.0 g of DM was added to the dissolution syringe. The outlet of the syringe was plugged and the 
syringe put on the filling stand purge. The sample vial was carefully submerged into liquid nitrogen 
(vertical position to avoid splashing) and allowed to freeze (2 min). The FP was then flushed with 
helium for 2 min after which the system was pressure tested (40 psi for 2 min without losing 
pressure). When the FP tests were completed, the valve rotor was inserted and put into the closed 
position. The dissolution syringe was then connected to a part B, Fig 1. Ca. 15.0 g of NM and 26.2 
g of DM were added to the receiver of part B, a Medrad power injector syringe was attached and the 
FP and receiver were ready to be inserted into the polarizer and QC module, respectively. 
b. Addition of small samples 
The filling tube was cleaned, dried and attached to a 1 mL syringe. Sample (40 µL) was placed in 
an Eppendorf tube, and drawn into the filling tube as a bolus, followed by ca. 10 cm air 
(Supplementary data Video 1). The filling tube was carefully inserted into the FP and pushed to the 
bottom of the vial. It was then retracted 0.5 cm. The syringe was removed, and helium was flushed 
through the filling tube (10 psi, 2 min) (Supplementary data Video 2). The filling tube was then 
removed from the FP. 13.3 g of DM and 138 µL NM were then added to the dissolution syringe. 
The FP was pressure tested as described for large samples. A short exit tube was attached (50 cm) 
and the FP was ready for being inserted into the polarizer. An empty 50 mL Falcon tube was used 
as a receiver for small samples.  
SPINlab QC (online measurements; large sample only) 
The QC module measures six parameters by methods that are non-contact with the product. The 
syringe valve is open for 10 s during the dissolution. The dissolution takes approx. 6 s. 5 s after the 
syringe valve closes, a part of the hyperpolarized sample is allowed to flow through a series of 
cavities by opening a valve in the bottom of the receiver. The QC parameters are measured in 
approx. 15 s, which means that the product (in the Medrad syringe) is released approx. 30 s after the 
dissolution is initiated. Pyruvate concentration is determined by absorbance at 360 nm, EPA 
concentration is determined by absorbance at 470 nm, pH is determined by ratio metric absorbance 
at 405 and 450 nm for a hydroxypyrene-1,3,6-trisulfonic acid (HPTS) dye in one of the cavities, 
polarization is measured by NMR and corrected for relaxation, temperature is measured by IR on 
the receiver and volume is a capacitance threshold sensor on the Medrad syringe. The QC module 
was calibrated prior to the experiments. Pyruvate concentration, EPA concentration and pH all 
required measurement of a dark, blank and several calibrants (GE Healthcare, USA) according to 
manufacturer’s instructions. Polarization and flip angle calibration were performed by the use of a 
13C reference sample (13C3-glycerol doped to shorten T1, QC daily check sample, GE Healthcare, 
USA) according to manufacturer’s instructions. Temperature was calibrated by the use of a receiver 
filled with water of known temperature.   
Offline measurements 
pH: LAQUA pH/ION meter F-72 (HORIBA) with pH electrode DJ 113 662-1385 (VWR) or Knick 
Portamess pH-meter 913 with pH electrode Hamilton mini electrode (KLC). Polarization: measured 
on a 400 MHz NMR (Agilent Technologies, USA). Acquisition parameters: 3⁰ flip angle every 2 s, 
starting approx. 10 s post dissolution. The thermal signal was acquired by adding Omniscan (15 µL) 
to reduce T1 to <1 s. 2000 averages with repetition delay 0.5 s, 3⁰ flip angle. Software for analysis: 
MestReNova 10.0 and MATLAB R2015a, by which polarization and T1 were calculated. PA 
concentration: For large samples the concentration was measured by quantitative NMR. Sample: 
sample from receiver (450 µL), [13C]urea (15 µL, 400 mM), D2O (100 µL) and Omniscan (15 µL). 
Acquisition parameters: 90⁰ flip angle, repetition delay 1.5 s. Software for analysis: TopSpin 3.2. 
For small samples the concentration was measured by absorbance on a BioTek EPOCH 2 
microplate reader (Holm & Halby, Brøndby, Denmark) at wavelength 360 nm. Temperature was 
measured by the use of thermometers of type OMEGA HH804U Thermometer or Testo 110, AG 
Germany. EPA concentration: measured by absorbance at 465 nm (EPOCH plate reader with 10 
mm cell). Output volumes were measured by weighing an empty Falcon tube before and after 
dissolution (Discovery Ohaus balance). 
 
RESULTS 
a. Large samples 
Eleven experiments were performed using four FP. The samples were polarized for 2.5 h on 
average to more than 90% of maximum polarization, followed by dissolution. The data from the QC 
module have been compared to offline measurements of the respective samples, Table 1. To secure 
a physiological acceptable pH, the NM in the receiver was adjusted accordingly to the amount of 
PA added (PA/NaOH ratio 1.6), which was in the range of 13.9-14.6 g. The target concentration in 
the case of large samples was 250 mM, which mimics a human dose. 
Table 1 - Results from dissolutions compared to the respective off-line measurements (n=11) 
 Average Standard deviation Relative STD (%)  
 







DM in syringe (g) 38.0 0.1 0.2 
DM in receiver (g) 








PA/NaOH mol ratio                    1.6 0.002 0.2 
 
Online results 
   
Pyruvate conc. (mM) 246 19 7.7 
pH 7.71 0.17 2.2 
EPA conc. (µM) 1.17 0.28 24 
Temperature (⁰C) 32.0 1.3  4.0 
Volume (mL) >40 mL             
Polarization (%) 34.2 2.9 (n=3)* 8.5 
 
Offline results 
   
Pyruvate conc. (mM) 247 20 8.3 
pH 7.75 0.15 1.9 
EPA conc. (µM) 0.68 0.21 31 
Volume (mL) (product 
in Medrad syringe) 
44.2 1.0 2.3 
Temperature (⁰C) 31.7 0.5 1.6 
 
* The NMR flip angle was incorrectly calibrated in the first experiments leading to saturation of the receiver and 
incorrect estimation of the polarization.  
b. Small samples 
To demonstrate filling of small samples, seven experiments were performed, Table 2, using the 
same four FP as in the large sample study. The experiments were designed to mimic a target 
concentration, suitable for small animal dose (80 mM). Polarization measurements were made for 
four of these. 
Table 2  – Results from dissolutions with small sample filling (n=7) 
 Average Standard deviation Relative STD (%) 
PA/EPA added (mg)* 40   
DM in syringe (g) 13.4           0.6 4.5 
NaOH (10M) syringe (g) 0.138   
 







pH 7.8 0.1 2 
EPA conc. (µM) 70.5 7.5 11 
Product in receiver (g) 5.3 0.6 12 
Temperature (⁰C) 54 2.6 5 
Polarization (%) 43.7 5.5 (n=4) 13 
T1 53.8 2.0 (n=4) 4 
Recovery (%) 82 12 15 
* 40 mg was assumed to be added with no loss under the addition process 
 
DISCUSSION 
The study shows that the new filling method of the FP can be performed in a reproducible manner, 
validated by QC parameters from the SPINlab and offline measurements. The method is robust with 
small relative standard deviations. We have demonstrated two extreme conditions; filling of large 
samples mimicking a human clinical dose, and small samples suited for small animal studies.  
For the human dose, base is added to the receiver, in order for the radical to precipitate and be 
filtered off before entering the receiver. The acceptance criterion for residual EPA in the product is 
less than 3 µM [18]. The measured value is 1.2±0.3 µM, well within specification, and 
demonstrating >99% removal. The mean value of the EPA concentration is five standard deviations 
below the acceptance criterion. The pyruvate concentration acceptance criteria are 220-280 mM 
[18], which is also achieved with three standard deviations margin. The acceptance criteria for pH 
are 6.7-8.2 [18]. The study was not perfectly centered in the range, which could be achieved by 
changing the volume of NM in the receiver. However, the range is about ten standard deviations in 
this study. pH is a critical safety parameter, demonstrating that filling and process performed very 
well and is robust. Since only approx. 44 mL are transferred to the Medrad syringe, recovery has 
been disregarded in the large sample case, since some of the sample is used in the QC and thereby 
trapped in the dead volume of the system. However, the volume transferred to the Medrad syringe is 
four standard deviations above the acceptance criterion. The FP’s have been reused for 
demonstrational purposes and are not sterile, but we believe the approach could be translated into a 
low bioburden version by appropriate cleaning of the FP before filling. Sterility assurance can then 
be achieved by a validated, in-line sterile filter. The filling procedure should be compatible with 
normal pharmacy clean room environments. 
For small samples, base is added to the dissolution syringe, which means that all the PA and EPA is 
transferred to the receiver upon dissolution, and recovery can thereby be estimated. Recovery is 
calculated from the product of pyruvate concentration and volume, and assume that the full 40 mg 
was deposited in the sample vial. Most of the 15-20% loss of sample is likely due to loss in the 
filling process. The pyruvate concentration in the receiver is highly linked to the performance of the 
fluid path, since the dead volume vary. The variability of 11% for the pyruvate concentration is 
acceptable for most animal studies. We have not systematically studied the minimal possible sample 
amount that can be deposited in the vial by our method, but we have tested volumes down to 10 mg. 
This could have significance for e.g. cell or perfused organ studies that only require dilute substrate 
concentrations. More important is the minimal volume that can be applied in the dissolution. We 
believe that the product volume of app 5 mL achieved in this study, is close to the minimum volume 
that can be reached without loss of polarization and reduced recovery. This is close to the same 
performance as e.g. the Hypersense optimized for small sample polarization. It would be reasonable 
to expect that the use of two-phase dissolution could reduce the effective dissolution volume even 
further as previously demonstrated [19]. 
The lower temperature of the solvent in the dissolution allows the use of all plastic components. 
Plastic components eliminates leaching of paramagnetic ions from e.g. stainless steel components 
and potential enhanced relaxation from these ions. The polyphenylsulfone that is used in the fluid 
path is a plastic with high toughness and impact strength, good long-term hydrolytic stability and 
chemical resistance. It withstands steam sterilization without any significant loss of properties. For 
other solvents than water, the chemical resistance at the given temperature and pressure conditions 
needs to be taken into consideration and tested. 
The SPINlab corrects the polarization to the start of dissolution by assuming a T1 of 65 s. This 
means that the measured polarization is corrected by a factor of approx. 1.5 in this study. The 
polarization for low dose is the actual measurement without any correction. However, the delay is 
only approx. 10 s from start of dissolution to measurement. The difference in polarization for the 
two situations is partly due to the higher magnetic field strength of the prototype polarizer (6.7 T vs 
5.0 T), but also that some polarization loss is known to occur in the QC system.   
The reusability of the FP’s means reduced cost for research purposes, and no failed FP were 
observed within the ten times reuse that we arbitrarily defined as the maximum number of reuses on 
the SPINlab. The filling method has been tested extensively (>100 dissolutions) at Aarhus 
University Hospital, Skejby on the SPINlab, without failure of the fluid path during dissolution that 
have led to contamination of the polarizer. Failure in dissolution can happen due to e.g. moisture in 
the tubing that lead to blockage and prevention of flow. This happens at a low rate depending on 
operator skills. In our laboratory we use the fluid paths until failure since contamination of the 
polarizer is easier to clean. However, most failures occur during handling as fatigue of glue joints, 
typically after 20-50 uses. Wear and tear can also lead to failure in the pressure test and discard of 
the fluid path. More rarely the FP fails early in use due to defects in the plastic. The failures due to 
defects in the plastic appear to be unrelated to the filling method, but can lead to a burst inside the 
polarizer during dissolution depending on location of the defect. With the hundreds of dissolutions 
that we have performed with this method, there does not seem to be a higher frequency of fatal 
incidents than by single use. 
 
CONCLUSION 
The principle of the fluid path for dissolution-DNP enables independent control of solvent 
temperature and flow rate. The benefit is efficient dissolution at lower solvent temperature and use 
of all plastic components. The reproducibility of the dissolution process is high on all parameters 
relevant for clinical use. The fluid path can be used for any sample size from 10 uL to 1.1 mL, and 
produces a minimum product volume of approx. 5 mL up to the full volume of 44 mL for a patient. 
 
ACKNOWLEDGEMENTS 
Rigshospitalet, Copenhagen, Denmark, is acknowledged for providing access to the SPINlab. 
Aarhus University Hospital, Skejby, Denmark, is acknowledged for testing the procedure and 
confirming reliability and performance. Furthermore, the authors wish to thank Danish National 




[1]  J. H. Ardenkjær-Larsen, B. Frindlund, A. Gram, G. Hansson, L. Hansson, M. H. Lerche, R. Servin, M. 
Thaning and K. Golman, "Increase in signal-to-noise ratio of >10,000 times in liquid state NMR," PNAS, 
vol. 100, no. 18, pp. 10158-10163, 2003.  
[2]  S. Kohler, Y. Yen, J. Wolber, A. Chen, M. Albers, R. Bok, V. Zhang, J. Tropp, S. Nelson, D. Vigneron , J. 
Kurhanewicz and R. Hurd, "In Vivo13Carbon Metabolic Imaging at 3T With Hyperpolarized13C-1-
Pyruvate," Magn. Reson. Med., vol. 58, pp. 65-69, 2007.  
[3]  H. Gutte, A. E. Hansen, H. H. Johannesen, A. E. Clemmensen, J. H. Ardenkjær-Larsen, C. H. Nielsen and 
K. Andreas, "The use of dynamic nuclear polarization (13)C-pyruvate MRS in cancer," Am. J. Nuc. Med. 
Mol. Imaging, vol. 5, pp. 548-560, 2015.  
[4]  K. Golman, R. in’t Zandt, M. Lerche, R. Pehrson and J. H. Ardenkjaer-Larsen, "Metabolic Imaging by 
Hyperpolarized 13C Magnetic Resonance Imaging for In vivo Tumor Diagnosis," Cancer Res., vol. 66, 
no. 22, pp. 10855-10860, 2006.  
[5]  S. Meier, P. R. Jensen and J. Ø. Duus, "Real-time detection of central carbon metabolism in living 
Escherichia coli and its response to perturbations," FEBS Lett., vol. 585, pp. 3133-3138, 2011.  
[6]  F. A. Gallagher, M. I. Kettunen, D.-E. Hu, P. R. Jensen, R. in't Zandt, M. Karlsson, A. Gisselsson, S. K. 
Nelson, T. H. Witney, S. E. Bohndiek, G. Hansson, T. Peitersen, M. H. Lerche and K. M. Brindle, 
"Production of hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis 
and treatment response in tumors," PNAS, vol. 106, no. 47, pp. 19801-19806, 2009.  
[7]  F. A. Gallagher, M. I. Kettunen and K. M. Brindle, "Imaging pH with hyperpolarized 13C," NMR BIOMED, 
vol. 24, pp. 1006-1015, 2011.  
[8]  C. von Morze, P. E. Larson, S. Hu, H. A. Yoshihara, R. A. Bok, A. Goga, J. H. Ardenkjær-Larsen and D. B. 
Vigneron, "Investigating tumor perfusion and metabolism using multiple hyperpolarized 13C 
compounds: HP001, pyruvate and urea," Magn. Reson. Imgaing, vol. 30, pp. 305-311, 2012.  
[9]  K. W. Lipsø, P. Magnusson and J. H. Ardenkjær-Larsen, "Hyperpolarized 13C MR Angiography," Curr. 
Pharm. Design, vol. 22, pp. 90-95, 2016.  
[10]  J. Ardenkjaer-Larsen, S. Macholl and H. Jóhanneson, "Dynamic Nuclear Polarization with Trityls at 1.2 
K," Appl. Magn. Reson., vol. 34, pp. 509-522, 2008.  
[11]  L. Lumata, S. J. Ratnakar, A. Jindal, M. Merritt, A. Comment, C. Malloy, A. D. Sherry and Z. Kovacs, 
"BDPA: An Efficient Polarizing Agent for Fast Dissolution Dynamic Nuclear Polarization NMR 
Spectroscopy," Chem. Eur. J., vol. 17, pp. 10825-10827, 2011.  
[12]  B. v. d. Brandt, E. Bunyatova, P. Hautle and J. Konter, "DNP with the free radicals deuterated TEMPO 
and deuterated oxo-TEMPO," Nucl. Instrum. Meth. A, vol. 526, pp. 53-55, 2004.  
[13]  S. J. Nelson, J. Kurhanewicz, D. B. Vigneron, P. E. Z. Larson, A. L. Harzstark, M. Ferrone, M. van 
Criekinge, J. W. Chang, R. Bok, I. Park, G. Reed, V. K. Weinberg, J. H. Ardenkjær-Larsen, A. P. Chen, R. E. 
Hurd, L.-I. Odegardstuen, F. J. Robb, J. Tropp and J. A. Murray, "Metabolic Imaging of Patients with 
Prostate Cancer Using Hyperpolarized [1-13C]Pyruvate," Sci. Transl. Med., vol. 5, no. 198, pp. 1-11, 
2013.  
[14]  A. Comment, J. Rentsch, F. Kurdzesau, S. Jannin, K. Uffmann, R. van Heeswijk, P. Hautle, J. Konter, B. 
van den Brandt and J. van der Klink, "Producing over 100 ml of highly concentrated hyperpolarized 
solution by means of dissolution DNP," J. Magn. Reson, vol. 194, pp. 152-155, 2008.  
[15]  S. Bowen and J. H. Ardenkjaer-Larsen, "Enhanced performance large volume dissolution-DNP," J. 
Magn. Reson., vol. 240, pp. 90-94, 2014.  
[16]  J. H. Ardenkjær-Larsen, A. M. Leach, N. Clarke, J. Urbahn, D. Anderson and T. W. Skloss, "Dynamic 
Nuclear Polarization Polarizer for Sterile Use Intent," NMR Biomed., vol. 24, pp. 927-932, 2011.  
[17]  J. Jain, S. Dey, L. Muralidharan, A. M. Leach and J. H. Ardenkjær-Larsen, "Jet Impingement Melting With 
Vaporization: A Numerical Study," in ASME Heat Transfer Summer Conference, Jacksonville, Florida, 
2008.  
[18]  "Hyperpolarized [13C] Pyruvate Documentation Page," National Cancer Institute - the National 
Institute of Health, [Online]. Available: http://imaging.cancer.gov/programsandresources/cancer-
tracer-synthesis-resources/hyperpolarized-C13-pyruvate-documentation. [Accessed 28 06 2016]. 
[19] T. Harris, C. Bretschneider, L. Frydman, Dissolution DNP NMR with solvent mixtures: Substrate 







Fig 1: (A) SPINlab polarizer. The polarizer operates at 5 T and 0.9 K [16]. The polarizer has four 
independent channels that allow simultaneous polarization of up to four samples (fluid paths). The 
QC module (cylindrical black unit) is seen to the right of the photo below the touch screen. (B) 
Fluid Path (FP). Part A: (1) vial (2) dynamic seal (3) co-axial tube (4) valve (5) dissolution syringe. 
Part B: (6) transfer tube (7) EPA filter (8) receiver vessel (9) QC appendage (10) sterile assurance 
filter (11) Medrad 65 mL MR syringe. Part A loads into the polarizer (behind the sliding door). The 
vial is inserted into one of the four airlock and the dissolution syringe is inserted into the 
corresponding heater-pressure module. After some pump-flush cycles, the airlock gate-valve will 
open and the vial can be pushed through the dynamic seal to the to the 0.9 K sample space. Part B is 
initially loaded into the corresponding warmer module seen to the lower right in (A). Shortly before 
dissolution part B is moved from the warmer to the QC module. 
 
Fig 2: (A) PEEK tube (a), sleeve (b), adapter (c), ferrule (e) and screw (f) assembled to result in the 
filling tube used for filling of the FP (B) Filling tube placed in correct position in a demonstrational 
set-up (C) section of a vial with sample; (1) outer lumen (2) inner tube (3) nozzle (4) sample 
(pyruvic acid) 
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